Risperidone Enhances the Vulnerability to Stroke in Hypertensive Rats

CNS Neuroscience and Therapeutics

Volumn 18, Issue 4, 2012, Pages 343-349

  Song, Shu Wei ^a   Sun, Yang ^a   Su, Bei Lin ^a   Liu, Chong ^a   Yang, Chu ^a   Godfraind, Theophile ^a,b   Su, Ding Feng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

Apoptosis; Hypertension; Risperidone; Stroke

Indexed keywords

GLUTATHIONE PEROXIDASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MALONALDEHYDE; PROTEIN BAX; RISPERIDONE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; DISEASE PREDISPOSITION; ENDOTHELIUM INJURY; ENZYME ACTIVITY; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL; NONHUMAN; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL TIME; TISSUE INJURY;

ANIMALS; APOPTOSIS; CELLS, CULTURED; HYPERTENSION; NEURONS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RISPERIDONE; STROKE;

EID: 84859499678     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2012.00302.x     Document Type: Article

References (42)

1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008;371:1612-1623.
2. Cushman M, Cantrell RA, McClure LA, et al. Estimated 10-year stroke risk by region and race in the United States: Geographic and racial differences in stroke risk. Ann Neurol 2008;64:507-513.
3. Yu JG, Zhou RR, Cai GJ. From hypertension to stroke: mechanisms and potential prevention strategies. CNS Neurosci Ther 2011;17:577-584.
4. + cells contributes to the susceptibility of stroke-prone spontaneously hypertensive rats. CNS Neurosci Ther 2011;17:327-332.
5. Mackay J, Mensah G. The atlas of heart disease and stroke. Geneva, Switzerland: World Health Organization, 2004.
6. Pajonk FG. Risperidone in acute and long-term therapy of schizophrenia-a clinical profile. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:15-23.
7. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685-693.
8. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57-73.
9. Wooltorton E. Risperidone (Risperdal): Increased rate of cerebrovascular events in dementia trials. Can Med Assoc J 2002;167:1269-1270.
10. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: Self controlled case series study. BMJ 2008;337:616-618.
11. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischemic stroke: Population based retrospective cohort study. BMJ 2005;330:445-448.
12. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004;161:1113-1115.
13. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010;170:96-103.
14. Committee on Safety of Medicines. Atypical antipsychotic drugs and stroke: Message from Professor Gordon Duff, chairman, (CEM/CMO/2004/1). London: Committee on Safety of Medicines, 2006.
15. Mowat D, Fowlie D, MacEwan T. CSM warning on atypical psychotics and stroke may be detrimental for dementia. BMJ 2004;328:1262.
16. European Pharmacovigilance Working Party (PhVWP). Public assessment report on antipsychotics and cerebrovascular accident. London: Medicines and Healthcare Products Regulatory Agency, 2006.
17. Curtis D. Effect of antipsychotics on stroke risk remains unproved. BMJ 2008;337:647.
18. Rosack J. Antipsychotics do not appear to increase stroke risk. Psychiatric News 2004;39:22-23.
19. Pratt NL, Roughead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for stroke associated with antipsychotic use in the elderly: A self-controlled case series. Drugs Aging 2010;27:885-893.
20. Song SW, Liu AJ, Bai C et al. Blood pressure reduction combining baroreflex restoration for stroke prevention in hypertension in rats. Front Pharmacol 2010;1:6. doi:
21. Wiart M, Davoust N, Pialat JB, et al. MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke 2007;38:131-137.
22. Zhu W, Fan Y, Hao Q, et al. Postischemic IGF-1 gene transfer promotes neurovascular regeneration after experimental stroke. J Cereb Blood Flow Metab 2009;29:1528-1537.
23. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990;10:290-293.
24. Xia Z, Luo T, Liu HM, Wang F, Xia ZY, Irwin MG, Vanhoutte PM. L-Arginine enhances nitrative stress and exacerbates TNF-Alpha toxicity to human endothelial cells in culture: Prevention by propofol. J Cardiovasc Pharmacol 2010;55:358-367.
25. Zhang XH, Lei H, Liu AJ, Zou YX, Shen FM, Su DF. Increased oxidative stress is responsible for severer cerebral infarction in stroke-prone spontaneously hypertensive rats. CNS Neursci Ther 2011;17:590-598.
26. Li DJ, Evans R, Yang ZW, et al. Dysfunction of cholinergic anti-inflammatory pathway in hypertensive rats. Hypertension 2011;57:298-307.
27. Zhang W, Shin EJ, Wang T, et al. 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB 2006;20:2496-2511.
28. Unal-Cevik I, Kilinc M, Can A, Gursoy-Ozdemir Y, Dalkara T. Apoptotic and necrotic death mechanisms are concomitantly activated in the same cell after cerebral ischemia. Stroke 2004;35:2189-2194.
29. Ukai W, Ozawa H, Tateno M, Hashimoto E, Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: Implication of Akt-mediated signal changes by haloperidol. J Neural Transm 2004;111:667-681.
30. Wang P, Xu TY, Guan YF, et al. Nampt protects against ischemic stroke through SIRT1-dependent AMPK pathway. Ann Neurol 2011;69:360-374.
31. Ma H, Guo R, Yu L, Zhang Y, Ren J. Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: Role of autophagy paradox and toxic aldehyde. Eur Heart J 2011;32:1025-1038.
32. Lev EI, Leshem-Lev D, Mager A, et al. Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis. Eur Heart J 2010;31:2625-2632.
33. Vogler M, Walczak H, Stadel D, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009;69:2425-2434.
34. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010;31:1771-1779.
35. Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res 2009;18:7-26.
36. Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003;64:1106-1112.
37. Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: Examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc 2004;5:129-132.
38. Daneshtalab N, Smeda JS. Alterations in the modulation of cerebrovascular tone and blood flow by nitric oxide synthases in SHR-SP with stroke. Cardiovasc Res 2010;86:160-168.
39. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2008;40:e331-e339.
40. Wang X. The anti-apoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther 2009;15:345-357.
41. Adams JM. Ways of dying: Multiple pathways to apoptosis. Genes Dev 2003;17:2481-2495.
42. Danlal NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004;116:205-219.